Tirz is FDA-approved, sold as Mounjaro (diabetes) and Zepbound (weight management) by Eli Lilly. The brand-name sticker, $1,000+ a month, prices most people out without insurance, so a parallel market of compounded tirzepatide has built up at $229–349/month through tele-doc platforms and 503A pharmacies (GLP-1 After Denial, 2026). That gap is why so many of us are on compounded right now, and why quality and legality swing hard depending on where you source.
The 72-week SURMOUNT-5 head-to-head against semaglutide, 20.2% weight loss vs. sema's 13.7% (NEJM, 2025), is what made tirz the most chased weight-loss compound of 2025–2026. Know the legal access routes before you pin anything.
Key Takeaways
- —Tirzepatide (Mounjaro/Zepbound) is FDA-approved. Three real routes: brand with insurance, compounded via 503A pharmacy with a script, or LillyDirect cash-pay ($299–449/month).
- —503A compounding stays legal while tirz is on the FDA shortage list. The FDA has already sent thousands of warning letters to platforms making bioequivalence claims about compounded GLP-1s.
- —The API in any compounded tirz must come from an FDA-registered manufacturer. That's the single most important quality check.
- —Compare tirz vs sema side-by-side using the Next Pep comparison tool before locking a protocol.
Tirz is a dual GIP/GLP-1 receptor agonist, the first approved peptide that hits both incretin pathways at once. Brand-name Zepbound (the weight-loss indication) lists at roughly $1,060/month for the maintenance dose, though out-of-pocket swings hard depending on coverage (Empower Pharmacy, 2025). Without coverage or a manufacturer coupon, that price kills sustained use.
Lilly's LillyDirect cash-pay program runs $299–449/month, but with geographic restrictions and ongoing supply hiccups. The space between clinical demand and what people can actually afford is exactly why 503A compounded tirz blew up.
Three legal paths, each with different quality implications.
1. Brand Mounjaro or Zepbound through a doctor. The only fully FDA-approved route. GMP-manufactured, full regulatory traceability, carries the clinical trial data behind it. Insurance, prior auths, and price are the wall.
2. 503A compounding pharmacy with a script. While tirz sits on the FDA drug shortage list, licensed 503A pharmacies can legally compound it for individual patients with a valid prescription. 503A requires sterile compounding under USP <797> standards, but doesn't carry the same GMP manufacturing controls as brand. The API has to come from an FDA-registered supplier. Pharmacies sourcing API from non-registered overseas chemical houses are operating outside compliance (FDA guidance, 2026).
3. 503B outsourcing facilities. Stricter GMP-adjacent standards than 503A, and they can run larger batches. Some 503Bs have been in the GLP-1 compounding game. They get more intense FDA oversight and periodic inspections.
Compounded tirz quality varies pharmacy to pharmacy. These are the checks that actually matter.
API source. Ask the pharmacy directly: does the tirz API come from an FDA-registered manufacturer? A PCAB-accredited pharmacy will answer it straight. Vague answers, or anything that points overseas, is a real flag.
Batch-specific COA. The pharmacy should hand you a cert of analysis for the exact batch dispensed: concentration confirmation (usually 2.5 mg/0.5 mL or 5 mg/0.5 mL), sterility testing, endotoxin assay. Tirz is a subq pin, so sterility and endotoxin burden aren't optional.
PCAB accreditation. Not every 503A is PCAB-accredited. The ones that are have passed independent facility audits and quality system reviews. It's the cleanest signal you'll get on a pharmacy's quality posture.
Beyond-use dating. Compounded tirz should carry a specific beyond-use date, not a hand-wave like "refrigerate and use within X weeks." USP-based BUD for sterile injectables accounts for the formulation, container closure, and storage conditions.
Imported API from non-FDA-registered facilities. This is the single biggest quality risk in the compounded GLP-1 market. Some operations are pulling tirz API from overseas chemical houses with no FDA registration, meaning the active ingredient hasn't been inspected against US pharma standards. The CT Attorney General sued one GLP-1 distributor in 2025 specifically over undisclosed overseas API sourcing.
Bioequivalence claims. Platforms that explicitly say their compounded tirz is "equivalent to Zepbound" or "the same active ingredient" are making claims the FDA has flat-out prohibited via warning letters. The chemistry is slightly different (tirzepatide base vs. tirzepatide salt). Whether that affects clinical outcomes is unknown, and that uncertainty is what the FDA warning is about.
No physician involvement. Legit telehealth platforms run a synchronous or asynchronous clinical eval before they prescribe. Platforms that fire off scripts off a questionnaire with zero clinician review of labs or history aren't running medical oversight, they're running access. Not the same thing.
Missing beyond-use date. Any injectable without a specific BUD on the label should go straight back.
Before you pick a tele-doc or pharmacy, knowing what tirz actually is, and where it diverges from sema, makes the clinical conversation way more productive. The tirzepatide research profile on Next Pep covers the dual GIP/GLP-1 mechanism, the SURMOUNT-5 72-week head-to-head data, and pharmacokinetics in one place. The peptide library gives you the full tirz and sema profiles side-by-side in structured, citation-backed format.
If you're deciding between tirz and sema, the comparison tool puts them next to each other so you can weigh mechanism and evidence before walking into a consult. Once you've got a script, the dosing calculator handles the math for any injectable peptide. Drop in your vial concentration and target dose, get exact draw volume and syringe units. Next Pep is the independent, non-commercial research reference. No referral fee, no platform stake, just the published data.
Compounded tirz uses tirzepatide base. Zepbound uses tirzepatide citrate (a salt form). The core peptide sequence is identical, but the formulations are chemically distinct. The FDA has explicitly prohibited advertising that calls them equivalent. There's no head-to-head clinical equivalence study. For most people the practical difference may be negligible, but it's not established, and any platform claiming bioequivalence is misrepresenting the current evidence.
Yes. While tirz stays on the FDA drug shortage list, 503A compounding pharmacies with a licensed physician's script can legally compound and dispense it. The shortage list status is under ongoing review. If tirz comes off the shortage list (the way sema did in early 2025), compounding legality changes overnight. Check current shortage list status at the FDA before you start a protocol.
At minimum: HbA1c and fasting glucose (metabolic baseline), lipid panel, comprehensive metabolic panel (kidney and liver function), TSH, and if relevant, a personal or family history screen for medullary thyroid carcinoma (a contraindication for GLP-1 agonists). Providers who put people on tirz with zero baseline metabolic labs aren't following evidence-based prescribing.
The SURMOUNT-5 72-week head-to-head RCT showed tirz hitting 20.2% weight loss vs sema's 13.7%, a statistically significant gap. Individual responses still vary, side effect profiles aren't identical (tirz tends to bring more sulfur burps and fatigue early), and cost/access shifts with insurance and geography. The Next Pep comparison tool lets you weigh both compounds against mechanism, dosing, and PK data before your clinical consult.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.